Record overview
Status and phase
Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1, PHASE2
Sponsor: GlaxoSmithKline
Condition: Multiple Myeloma
NCT04126200
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: primary_completion_date_past_signal | long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | rare_population_signal | strict_eligibility_signal | complex_intervention_signal
Stopped reason
Context when available
No stop reason available in the current public record.